Compare General Motors Company (GM) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Repligen Corporation Common Stock — how do they compare? General Motors Company trades at $83.17 (market cap $73.71B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: General Motors Company is far larger — about 6.6× Repligen Corporation Common Stock's market cap, and General Motors Company pays a 0.86% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Repligen Corporation Common Stock for 0 Days on average.
| GM | RGEN | |
|---|---|---|
Market Cap | $73.71B | $11.14B |
Volume | 6,224,747 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $194.57 |
52-Week Low | $57.34 | $102.87 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $176.68B | $11.02B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $83.05, up 0.83% with a bullish technical signal. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, though Q3 2026 results are pending. Valuation metrics appear reasonable with P/S of 0.42 and P/B of 1.19, while profitability remains modest with 1.05% net margin. Recent news highlights competitive pressures as Toyota narrows the U.S. sales gap and Q3 vehicle sales declined 5.5%.
GM faces near-term headwinds from declining sales and margin pressure, but analyst consensus remains bullish with a $102.33 price target representing 23% upside. The company benefits from regulatory savings and EV partnerships, though execution risks and market share erosion require monitoring. Cash flow stability and dividend payments provide shareholder support amid industry transition challenges.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
